TAK-733

DB12241InvestigationalSmall molecule

TAK-733 has been used in trials studying the treatment of Advanced Metastatic Melanoma, Advanced Nonhematologic Malignancies, and Advanced Non-hematologic Malignancies.

Mechanism: Pharmacologically active on Dual specificity mitogen-activated protein kinase kinase 1 and Dual specificity mitogen-activated protein kinase kinase 2
Curator reviewed
Formula / weight: C₁₇H₁₅F₂IN₄O₄ · 504.2267 g/mol (avg)
Also known as: (R)-3-(2,3-DIHYDROXYPROPYL)-6-FLUORO-5-(2-FLUORO-4-IODOPHENYLAMINO)-8-METHYLPYRIDO(2,3-D)PYRIMIDINE-4,7(3H,8H)-DIONE · 3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5-[(2-fluoro-4-iodophenyl)amino]-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione
Code names: TAK 733

Resolves to

Compound

UNII5J61HSP0QJCAS1035555-63-5ChEMBLCHEMBL1615025PubChem24963252

Structure

InChIKeyRCLQNICOARASSR-SECBINFHSA-NSMILES[H][C@](O)(CO)CN1C=NC2=C(C1=O)C(NC1=C(F)C=C(I)C=C1)=C(F)C(=O)N2C

Targets

Q02750MAP2K1P36507MAP2K2

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with TAK-733, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account